Kin-Hung Peony Yu
FibroGen Settles with SEC for $1.25M Over Roxadustat Data Tampering Allegations
FibroGen; SEC; roxadustat; data manipulation; settlement; Kin-Hung Peony Yu; phase 3 clinical trial; anemia drug; cardiovascular safety; FDA
Actionable Insights Powered by AI
FibroGen; SEC; roxadustat; data manipulation; settlement; Kin-Hung Peony Yu; phase 3 clinical trial; anemia drug; cardiovascular safety; FDA